Axogen had its Relative Strength (RS) Rating upgraded from 67 to 75 Monday — a welcome improvement, but still shy of the 80 or better score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary rating tracks share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History shows that the top-performing stocks tend to have an RS Rating north of 80 as they launch their largest runs. See if Axogen can continue to rebound and hit that benchmark.
Axogen is not currently showing a potential entry point. See if the stock goes on to build a base that could launch a new move.
Top and bottom line growth moved higher last quarter. Earnings were up 140%, compared to 0% in the prior report. Revenue increased from 17% to 18%.
The company holds the No. 15 rank among its peers in the Medical-Products industry group. Insulet, ResMed and TransMedics Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
